Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 479505, 13 pages
http://dx.doi.org/10.1155/2013/479505
Research Article

Berry and Citrus Phenolic Compounds Inhibit Dipeptidyl Peptidase IV: Implications in Diabetes Management

1College of Bioscience and Biotechnology, Beijing Forestry University, Beijing 100083, China
2Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA
3Plants for Human Health Institute, NC Research Campus, North Carolina State University, Kannapolis, NC 28081, USA
4Department of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign, Drive, Urbana, IL 61801, USA

Received 30 March 2013; Revised 1 July 2013; Accepted 1 July 2013

Academic Editor: Mohd Roslan Sulaiman

Copyright © 2013 Junfeng Fan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Nauck, T. Vilsbøll, B. Gallwitz, A. Garber, and S. Madsbad, “Incretin-based therapies: viewpoints on the way to consensus,” Diabetes Care, vol. 32, supplement 2, pp. S223–S231, 2009. View at Google Scholar · View at Scopus
  2. J. J. Holst and J. Gromada, “Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans,” American Journal of Physiology. Endocrinology and Metabolism, vol. 287, no. 2, pp. E199–E206, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. J. F. Gautier, S. Fetita, E. Sobngwi, and C. Salaün-Martin, “Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes,” Diabetes and Metabolism, vol. 31, no. 3, pp. 233–242, 2005. View at Google Scholar · View at Scopus
  4. L. L. Baggio and D. J. Drucker, “Biology of incretins: GLP-1 and GIP,” Gastroenterology, vol. 132, no. 6, pp. 2131–2157, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. J. J. Holst, T. Vilsbøll, and C. F. Deacon, “The incretin system and its role in type 2 diabetes mellitus,” Molecular and Cellular Endocrinology, vol. 297, no. 1-2, pp. 127–136, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. C. F. Deacon, “Circulation and degradation of GIP and GLP-1,” Hormone and Metabolic Research, vol. 36, no. 11-12, pp. 761–765, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Mentlein, “Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides,” Regulatory Peptides, vol. 85, no. 1, pp. 9–24, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. C. F. Deacon, M. A. Nauck, J. Meier, K. Hücking, and J. J. Holst, “Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 10, pp. 3575–3581, 2000. View at Google Scholar · View at Scopus
  9. E. P. Semighini, J. A. Resende, P. De Andrade et al., “Using computer-aided drug design and medicinal chemistry strategies in the fight against diabetes,” Journal of Biomolecular Structure and Dynamics, vol. 28, no. 5, pp. 787–796, 2011. View at Google Scholar · View at Scopus
  10. P. Jadav, R. Bahekar, S. R. Shah et al., “Long-acting peptidomimetics based DPP-IV inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 22, no. 10, pp. 3516–3521, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Janardhan, “Homology modeling and molecular docking studies of human DPP8 and DPP9,” International Journal of Pharma Research and Development, vol. 2, no. 12, pp. 131–146, 2011. View at Google Scholar
  12. N. González Abuín, N. Martínez-Micaelo, M. Blay et al., “Grape seed-derived procyanidins decrease dipeptidyl-peptidase 4 activity and expression,” Journal of Agricultural and Food Chemistry, vol. 60, pp. 9055–9061, 2012. View at Google Scholar
  13. H. S. Parmar, P. Jain, D. S. Chauhan et al., “DPP-IV inhibitory potential of naringin: an in silico, in vitro and in vivo study,” Diabetes Research and Clinical Practice, vol. 97, no. 1, pp. 105–111, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Knekt, J. Kumpulainen, R. Järvinen et al., “Flavonoid intake and risk of chronic diseases,” American Journal of Clinical Nutrition, vol. 76, no. 3, pp. 560–568, 2002. View at Google Scholar · View at Scopus
  15. N. M. Wedick, A. Pan, A. Cassidy et al., “Dietary flavonoid intakes and risk of type 2 diabetes in US men and women,” American Journal of Clinical Nutrition, vol. 95, no. 4, pp. 925–933, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Thomas and A. F. H. Pfeiffer, “Foods for the prevention of diabetes: how do they work?” Diabetes/Metabolism Research and Reviews, vol. 28, no. 1, pp. 25–49, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. H. Johnson, E. G. de Mejia, J. Fan, M. A. Lila, and G. G. Yousef, “Anthocyanins and proanthocyanidins from blueberry-blackberry fermented beverages inhibit markers of inflammation in macrophages and carbohydrate-utilizing enzymes in vitro,” Molecular Nutrition & Food Research, vol. 57, no. 7, pp. 1182–1197, 2013. View at Publisher · View at Google Scholar
  18. E. O. Cuevas-Rodríguez, G. G. Yousef, P. A. García-Saucedo, J. López-Medina, O. Paredes-López, and M. A. Lila, “Characterization of anthocyanins and proanthocyanidins in wild and domesticated mexican blackberries (Rubus spp.),” Journal of Agricultural and Food Chemistry, vol. 58, no. 12, pp. 7458–7464, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. M. H. Grace, D. M. Ribnicky, P. Kuhn et al., “Hypoglycemic activity of a novel anthocyanin-rich formulation from lowbush blueberry, Vaccinium angustifolium Aiton,” Phytomedicine, vol. 16, no. 5, pp. 406–415, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Hiramatsu, A. Yamamoto, K. Kyono et al., “The crystal structure of human dipeptidyl peptidase IV (DPPIV) complex with diprotin A,” Biological Chemistry, vol. 385, no. 6, pp. 561–564, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. R. R. S. Pissurlenkar, M. S. Shaikh, and E. C. Coutinho, “3D-QSAR studies of Dipeptidyl peptidase IV inhibitors using a docking based alignment,” Journal of Molecular Modeling, vol. 13, no. 10, pp. 1047–1071, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. G. M. Morris, H. Ruth, W. Lindstrom et al., “Software news and updates AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility,” Journal of Computational Chemistry, vol. 30, no. 16, pp. 2785–2791, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Wallerath, H. Li, U. Gödtel-Ambrust, P. M. Schwarz, and U. Förstermann, “A blend of polyphenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase,” Nitric Oxide, vol. 12, no. 2, pp. 97–104, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. A. E. Weber, “Dipeptidyl peptidase IV inhibitors for the treatment of diabetes,” Journal of Medicinal Chemistry, vol. 47, no. 17, pp. 4135–4141, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Bansal, P. Paul, J. Mudgal et al., “Antidiabetic, antihyperlipidemic and antioxidant effects of the flavonoid rich fraction of Pilea microphylla (L.) in high fat diet/streptozotocin-induced diabetes in mice,” Experimental and Toxicologic Pathology, vol. 64, no. 6, pp. 651–658, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Takasawa, K. Saeki, A. Tao et al., “Delphinidin, a dietary anthocyanidin in berry fruits, inhibits human glyoxalase i,” Bioorganic and Medicinal Chemistry, vol. 18, no. 19, pp. 7029–7033, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. A. P. Rauter, A. Martins, C. Borges et al., “Antihyperglycaemic and protective effects of flavonoids on streptozotocin-induced diabetic rats,” Phytotherapy Research, vol. 24, no. 2, pp. S133–S138, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. N. S. Kang, J. H. Ahn, S. S. Kim, C. H. Chae, and S.-E. Yoo, “Docking-based 3D-QSAR study for selectivity of DPP4, DPP8, and DPP9 inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 13, pp. 3716–3721, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. I. Arozarena, J. Ortiz, I. Hermosin-Gutierrez et al., “Color, ellagitannins, anthocyanins, and antioxidant activity of Andean blackberry (Rubus glaucus Benth.) wines,” Journal of Agricultural and Food Chemistry, vol. 60, pp. 7463–7473, 2012. View at Google Scholar
  30. M. W. Chang, C. Ayeni, S. Breuer, and B. E. Torbett, “Virtual screening for HIV protease inhibitors: a comparison of AutoDock 4 and Vina,” PLoS ONE, vol. 5, no. 8, Article ID e11955, 2010. View at Publisher · View at Google Scholar · View at Scopus